Cosciens Biopharma (CSCI) Corporate presentation summary
Event summary combining transcript, slides, and related documents.
Corporate presentation summary
13 Nov, 2026Strategic transformation
Four directors appointed in May 2025; Ceapro and corporate cost reductions followed, alongside a strategic review focused on profitability and growth.
Ceased funding German subsidiaries in March 2026 and initiated insolvency proceedings; this eliminated ongoing operating-loss exposure and generated $10.9M of discontinued-operations income, with shareholders’ equity increasing 4X.
Shareholders approved a 1-for-150 consolidation followed by a 50-for-1 split; the share count fell by approximately two-thirds, and a July 2026 Form 15 filing was intended to save an estimated $1.9M in annual reporting costs.
Acquired Nualtis in September 2026 for $15M, with potential earn-outs of 10% of adjusted EBITDA for FY2027–FY2030; Nualtis adds oral-film technology and pharmaceutical development and manufacturing capabilities.
Operating platforms
Ceapro develops and manufactures oat- and plant-derived actives for personal care, cosmetics, human health, and animal health; its Edmonton GMP facility supports R&D, pilot, and commercial production.
Ceapro’s portfolio includes oat beta glucan, avenanthramides, superfine oat flour, oat oil, and oat peptides; products serve skin care, hair care, sensitive skin, and animal and pet markets.
Ceapro’s proprietary extraction, chromatography purification, and PGX processing complement non-GMO oat inputs, quality documentation, and distribution partners across multiple markets.
Ceapro generates approximately $9M in revenue, growing at circa 5% annually, with an approximately $2M annualized EBITDA run rate; core assets include a 30,000 sq. ft. Edmonton GMP plant.
Nualtis operates a Montreal GMP facility and develops human and veterinary oral thin films through VersaFilm and VetaFilm; its platform is supported by 30+ U.S. patents and patent applications.
Nualtis market and pipeline
Oral thin films are cited as a $3.8B global market in 2024, projected to reach $8.4B by 2033 at a 9.3% CAGR; sublingual films represented 63% of the 2024 market.
Nualtis has 20+ years of R&D experience and a diversified human- and animal-health pipeline, with multiple assets in approval stages and revenue potential from services, manufacturing, milestones, and royalties.
Pipeline molecules include rizatriptan, buprenorphine, buprenorphine/naloxone, tadalafil, montelukast, and undisclosed candidates across indications including migraine, pain, opioid use disorder, and animal health.
A buprenorphine product is subject to ongoing patent litigation; an adverse outcome could materially delay its commercial launch.
Nualtis is expected to generate approximately $6M in 2026 revenue and be small EBITDA positive; successful pipeline commercialization could produce tens of millions of dollars in annual revenue within five years, with an approximately 40% EBITDA margin at that revenue level.
Latest events from Cosciens Biopharma
- Ceapro’s growing base and Nualtis’ oral-film pipeline anchor the growth strategy.CSCI
Corporate presentation - Revenue rose 70% as Nualtis expanded OTF, amid losses and liquidity risks.CSCI
Q3 2026 - Q2 2026 delivered higher sales, lower expenses, and a major turnaround in profitability.CSCI
Q2 2026 - Board re-elections, auditor appointment, and share consolidation/split were all approved.CSCI
AGM 2026 - Returned to profitability in Q1 2026, driven by discontinued operations and lower expenses.CSCI
Q1 2026 - Restructuring and subsidiary exit drove lower losses and improved cost structure in 2025.CSCI
Q4 2025 - Operating expenses fell 59% and net loss narrowed in Q3 2025 amid restructuring and Nasdaq delisting.CSCI
Q3 2025 - Q2 2025 saw revenue growth, cost cuts, Nasdaq delisting, and major leadership changes.CSCI
Q2 2025 - Six directors elected, auditor reappointed, and company name change approved; no questions asked.CSCI
AGM 2024